Cellectis SA (ALCLS) AI Stock Analysis

• Market Cap: $88.96M
• Dividend Yield: N/A
• Average Volume (3M): 66.50K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.53
• Revenue Growth: 833.95%
• EPS Growth: 38.17%
• Country: FR
• Employees: 216
• Sector: Healthcare
• Sector Strength: 46
• Industry: Biotechnology
• EPS (TTM): -0.16
• Shares Outstanding: 72,093,636
• 10 Day Avg. Volume: 56,058
• 30 Day Avg. Volume: 66,503
• PEG Ratio: -0.08
• Price to Book (P/B): 0.82
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.08
• Enterprise Value/Market Cap: 0.92
• Enterprise Value/Revenue: 0.92
• Enterprise Value/Gross Profit: 1.91
• Enterprise Value/Ebitda: -0.25
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 44 Neutral
• Price Target: €1.50 ▲(17.19%Upside)

Cellectis SA's stock score is significantly impacted by its financial performance and technical analysis. Persistent net losses and negative profit margins weigh heavily despite recent revenue growth. Technical indicators suggest bearish sentiment, with the stock underperforming across key moving averages. Valuation concerns are exacerbated by a negative P/E ratio and the absence of dividends, further impacting the overall score.

Cellectis SA Business Overview & Revenue Model

Company Description

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

How the Company Makes Money

Cellectis makes money primarily through the development and commercialization of its gene-editing technologies and therapies. The company generates revenue through strategic partnerships, licensing agreements, and collaborations with other pharmaceutical and biotechnology companies. These partnerships typically involve upfront payments, milestone payments, and royalties on sales of products that utilize Cellectis's technology. Additionally, Cellectis may receive funding from grants and research contracts to support its innovative research and development efforts.

Cellectis SA Financial Statement Overview

Summary

The financial performance of Cellectis SA shows mixed results. The income statement indicates significant revenue growth, but persistent net losses and negative profit margins remain a concern. The balance sheet reflects moderate stability with a manageable debt-to-equity ratio and a strong cash position, but negative net income impacts return on equity. Cash flow improvements are notable; however, the company’s reliance on financing activities to bolster cash reserves is a risk.

Income Statement

The income statement shows significant volatility with a recent revenue surge from $755,000 in 2023 to $41.5 million in 2024, marking a dramatic revenue growth, albeit from a low base. Despite this, the company has consistently posted net losses, with a net profit margin deeply negative at -88.6% in 2024. The EBIT and EBITDA margins are also negative, indicating ongoing operational challenges.

Balance Sheet

Cellectis SA's balance sheet reflects moderate financial stability with a debt-to-equity ratio of 0.70 in 2024, suggesting manageable leverage. The equity ratio is 34.2%, indicating a reasonable equity base. However, the persistent negative net income impacts return on equity, which remains negative. Overall, the balance sheet is supported by a strong cash position.

Cash Flow

The cash flow statement highlights an improvement in free cash flow, from a negative point in 2023 to a positive $19.1 million in 2024, showing promising operational cash flow management. The operating cash flow to net income ratio is positive, reflecting efficient cash generation relative to net losses. However, the company relies heavily on financing activities to bolster cash reserves.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
41.51M	755.00K	19.17M	73.95M	73.95M
	Gross Profit
41.51M	18.00K	17.40M	37.67M	37.67M
	EBIT
-59.55M	-97.30M	-89.67M	-85.44M	-85.44M
	EBITDA
-9.46M	-92.64M	-76.38M	-85.44M	-43.34M
	Net Income Common Stockholders
-36.76M	-101.06M	-98.69M	-86.28M	-72.57M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
260.31M	203.81M	97.70M	186.13M	268.24M
	Total Assets
383.54M	334.27M	261.22M	382.08M	469.47M
	Total Debt
91.46M	85.06M	82.85M	102.24M	111.30M
	Net Debt
-51.79M	-51.65M	-14.85M	-83.90M	-156.94M
	Total Liabilities
252.51M	249.57M	135.28M	145.60M	160.63M
	Stockholders Equity
131.03M	84.69M	117.97M	221.29M	275.57M
Cash Flow		Free Cash Flow
19.15M	-25.82M	-89.89M	-124.31M	-126.52M
	Operating Cash Flow
22.99M	-24.75M	-87.44M	-104.56M	-80.26M
	Investing Cash Flow
-102.81M	-15.51M	-2.76M	7.28M	-54.34M
	Financing Cash Flow
89.11M	82.86M	1.15M	47.52M	27.32M

Cellectis SA Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.28
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALCLS, the sentiment is Negative. The current price of 1.28 is below the 20-day moving average (MA) of 1.32, below the 50-day MA of 1.34, and below the 200-day MA of 1.57, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 35.13 is Neutral, neither overbought nor oversold. The STOCH value of 6.56 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:ALCLS.

Cellectis SA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	53 Neutral	$5.22B	3.33	-44.36%	7.55%	16.78%	-0.12%
ALCLS	44 Neutral	$88.96M	―	-58.55%	―	833.95%	38.17%
IPHYF		$175.24M	―	-160.99%	―	―	―
0QAV		€182.82M	―		―	―	―
0OCQ		€122.19M	―	-220.48%	―	―	―
6OP		€115.53M	2.89	86.78%	―	―	―
RFM		€105.51M	―	-49.28%	―	―	―

Cellectis SA Corporate Events

Cellectis Reports 2024 Financial Results and Strategic Advances in CAR T-Cell Therapies

Cellectis has announced its financial results for the fourth quarter and fiscal year 2024, alongside a business update. The company is advancing its clinical trials, particularly UCART22 and UCART20x22, with significant regulatory designations from the FDA and European Commission, enhancing its position in the CAR T-cell therapy market. Its strategic partnership with AstraZeneca, including a $140 million investment, supports the development of next-generation genomic medicines, with a strong cash position projected to last until mid-2027.

Cellectis Advances Clinical Programs and Strengthens AstraZeneca Partnership

Cellectis has reported its financial results for the fourth quarter and full year 2024, highlighting significant progress in its clinical programs and strategic partnerships. The company is advancing its UCART22 and UCART20x22 programs, with key data readouts expected in 2025. Cellectis has also strengthened its collaboration with AstraZeneca, which includes an additional equity investment of $140 million, ensuring financial stability until mid-2027. The company’s focus remains on developing next-generation genomic medicines to address unmet patient needs.